Takeda (NYSE:TAK) has announced that it has won manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid, a novel COVID-19 vaccine.
Nuvaxovid (NVX-CoV2373) was initially developed by Novavax (Nasdaq:NVAX).
The approval covers the use of the vaccine as both a primary and booster immunization in adults at least 18 years old.
Get the full story from our sister site, Drug Discovery & Development.